Pfizer jointly launch Lupus Research Study 23andMe.

The more insights that researchers can gain, the faster safer drugs can be developed. We look forward to working with 23andMe and Pfizer as we continue our initiatives to teach and engage people who have lupus on the need for participating in research as one of the most powerful methods to do something against lupus.’ Recruitment of eligible study individuals is expected to be finished by mid 2016.. 23andMe, Pfizer jointly launch Lupus Research Study 23andMe, Inc., the leading personal genetics business, today announced the launch of the Lupus STUDY in collaboration with Pfizer Inc.That re-evaluation was the focus of the hearings kept in May and July 2008. Related StoriesHealthcare technology sociable event of the year opens entriesDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixOJ Bio at Medica 2015 – Point of Care diagnostics' part in reducing antibiotics prescribingLeonard Web page was the exterior hearing officer appointed by the IEB. Page is the previous General Counsel of the National Labor Relations Panel, appointed by President Clinton in 1999. Page noticed and reviewed testimony given on May 6-7 and July 14-15, 2008 from each one of the locals in California that have long-term care people: Local 521, UHW, and Regional 6434. He also heard testimony from the Long-Term Care Division of SEIU Healthcare. After completing this review, Web page recommended the creation of a fresh long-term care regional union for California long-term care members, and the merger and consolidation of long-term care members from Local 521, Regional 6434 and UHW into this fresh California long-term care regional union.